GleamWall
中文EN

QDEL QuidelOrtho Corp

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1906324 · Fiscal year ends 01/01

Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.5%
TTM net income YoY68.7%
TTM EPS YoY69.0%
Revenue 3-yr CAGR-6.0%
Net income 3-yr CAGR—

Margins

Gross margin44.2%
Operating margin-4.9%
Net margin-14.2%
FCF margin-4.5%
EBITDA margin12.9%

Returns

ROE-19.3%
ROA-6.4%
ROIC (approx.)-2.2%
Asset turnover0.45x

Leverage & solvency

Liabilities / assets69.0%
Debt / equity1.64x
Current ratio1.36x
Interest coverage-0.60x

Cash quality & payout

Operating cash flow / net income-0.02x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue4.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-272026Q22026-06-282026Q12026-03-292025Q4*2025-12-282025Q32025-09-282025Q22025-06-292025Q12025-03-302024Q4*2024-12-29
Income statement
Revenue$618.90M$630.90M$619.80M$723.60M$699.90M$613.90M$692.80M$707.80M
Cost of revenue$329.30M$358.00M$356.00M$403.20M$364.30M$339.00M$349.50M$381.70M
Gross profit$289.60M$272.90M$263.80M$320.40M$335.60M$274.90M$343.30M$326.10M
R&D expense$42.50M$48.70M$44.90M$45.80M$41.50M$45.70M$53.20M$47.30M
SG&A expense$182.70M$189.70M$199.30M$194.40M$186.90M$178.00M$187.00M$187.50M
Operating income-$7.50M-$21.80M-$31.80M-$66.30M-$704.80M-$180.70M$32.60M-$100.40M
Interest expense$55.40M$54.70M$51.10M$51.00M$46.10M$40.50M$40.00M$40.60M
Pretax income-$62.90M-$81.20M-$79.50M-$112.40M-$756.90M-$229.60M-$8.80M-$140.90M
Income tax-$9.10M$11.70M$12.30M$18.30M-$23.90M$25.80M$3.90M$37.50M
Net income-$53.80M-$92.90M-$91.80M-$130.70M-$733.00M-$255.40M-$12.70M-$178.40M
EBITDA$112.10M$94.90M$81.10M$46.20M-$592.70M-$70.40M$139.70M$8.90M
EPS (basic)-0.78-1.36-1.35—-10.78-3.77-0.19—
EPS (diluted)-0.78-1.36-1.35—-10.78-3.77-0.19—
Weighted avg. shares (diluted)68.70M68.30M68.20M—68.00M67.70M67.50M—
Banking
Net interest income———————-$40.60M
Balance sheet
Cash & equivalents$166.40M$123.40M$140.40M$169.80M$98.10M$151.70M$127.20M$98.50M
Short-term investments———————$0
Receivables$375.50M$352.00M$359.90M$417.00M$386.50M$275.00M$286.00M$282.40M
Inventory$642.70M$618.90M$611.50M$577.60M$613.80M$578.70M$563.20M$533.70M
Current assets$1.45B$1.38B$1.38B$1.45B$1.37B$1.28B$1.26B$1.22B
PP&E, net$1.32B$1.34B$1.34B$1.36B$1.32B$1.31B$1.40B$1.38B
Goodwill———$0$0$711.10M$670.90M$649.50M
Intangibles$2.63B$2.68B$2.52B$2.56B$2.61B$2.66B$2.70B$2.74B
Total assets$5.78B$5.72B$5.63B$5.77B$5.68B$6.38B$6.46B$6.42B
Current liabilities$1.07B$993.40M$962.40M$966.10M$767.90M$1.14B$1.05B$998.80M
Short-term debt$424.40M$355.70M$228.20M$178.30M$162.50M$534.20M$393.80M$341.80M
Long-term debt$2.51B$2.54B$2.46B$2.47B$2.50B$2.07B$2.11B$2.14B
Total debt$2.94B$2.89B$2.69B$2.65B$2.66B$2.61B$2.50B$2.48B
Total liabilities$3.99B$3.94B$3.78B$3.85B$3.64B$3.59B$3.46B$3.44B
Shareholders' equity$1.79B$1.77B$1.85B$1.92B$2.04B$2.79B$3.00B$2.98B
Net debt$2.77B$2.77B$2.55B$2.48B$2.56B$2.45B$2.37B$2.38B
Shares outstanding68.60M68.30M68.10M67.90M67.90M67.70M67.50M67.30M
Cash flow statement
Operating cash flow$19.60M-$110.60M-$33.00M$131.90M-$45.50M-$46.80M$65.60M$63.70M
Capital expenditure$21.00M$25.50M$34.00M$45.30M$49.20M$37.50M$56.20M$47.20M
Free cash flow-$1.40M-$136.10M-$67.00M$86.60M-$94.70M-$84.30M$9.40M$16.50M
Investing cash flow-$20.90M-$107.30M-$34.00M-$49.60M-$53.90M-$33.00M-$56.20M-$37.90M
Financing cash flow$44.10M$200.60M$37.60M-$11.10M$46.00M$103.30M$17.60M-$68.90M
Depreciation & amortization$119.60M$116.70M$112.90M$112.50M$112.10M$110.30M$107.10M$109.30M
Stock-based compensation$12.00M$12.00M$10.70M$10.80M$10.80M$12.80M$11.60M$9.60M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.